Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RAG-01

Phase 1Small molecule

RRactigen Therapeutics.

RAG-01 is one of 39 small molecule programs targeting Bladder Cancer. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

38

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bladder CancerActive, not recruiting

Bladder CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

378 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Velban

Adriamycin

Taxotere

Keflex

Paraplatin

Aquasol E

NNational Eye Institute (NEI)

Mitomycin C

GGynecologic Oncology Group

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Bladder Cancer

NCT06351904

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Recruiting·RRactigen Therapeutics.·Phase 1·NCT06351904·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RAG-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RAG-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RAG-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ractigen Therapeutics. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRactigen Therapeutics.

Related News